Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study : Efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

✍ Scribed by Giuseppe Saglio; Andreas Hochhaus; Yeow Tee Goh; Tamas Masszi; Ricardo Pasquini; Frederic Maloisel; Philipp Erben; Jorge Cortes; Ronald Paquette; M. Brigid Bradley-Garelik; Chao Zhu; Herve Dombret

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 373 KB
• Volume: 116
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.25123